Articles By Anuja Singh
Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for…
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
By
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2…
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s $27B Manufacturing Expansion Reshape the Future…
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency…
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can Roche’s $700M Genentech Facility Drive Its $50B US Investment Strategy and Transform Obesity…
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…
Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for…
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2…
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s $27B Manufacturing Expansion Reshape the Future…
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency…
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can Roche’s $700M Genentech Facility Drive Its $50B US Investment Strategy and Transform Obesity…
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…